1-3 of 3
Fabrizio Quarantelli, PhD
Close
Sort by
Journal Articles

A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment

Nicola Esposito, PhD, Irene Colavita, PhD, Fabrizio Quarantelli, PhD, Barbara Izzo, PhD, Luigia Luciano, MD, Luigi Del Vecchio, MD, Timothy Hughes, Jerald Radich, Domenico Russo, MD, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Giovanni Martinelli, MD, Giuseppe Saglio, MD, Junia Melo, MD, PhD, Margherita Ruoppolo, PhD, Thea Kalebic, Fabrizio Pane, MD
Journal: Blood
Blood (2008) 112 (11): 3186.
https://doi.org/10.1182/blood.V112.11.3186.3186
Published: 2008
Journal Articles

Down-Modulation of Shp1 and Hsp70 Provides a Survival Advantage to the Ph+ Cells of CML Patients Additive to That Related to the Oncogenic BCR/ABL Protein and May Account for Resistance to Ima Treatment.

Nicola Esposito, PhD, Fabrizio Quarantelli, PhD, Barbara Izzo, PhD, Giada Muccioli Casadei, MD, Luigia Luciano, MD, Giuseppe Saglio, MD, Junia V. Melo, MD, Thea Kalebic, MD, Giovanni Martinelli, MD, Fabrizio Pane, MD
Journal: Blood
Blood (2007) 110 (11): 1014.
https://doi.org/10.1182/blood.V110.11.1014.1014
Published: 2007
Journal Articles

Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.

Giuliana Alimena, MD, Massimo Breccia, MD, Luigia Luciano, MD, Fabrizio Quarantelli, PhD, Daniela Diverio, PhD, Barbara Izzo, MD, Biagio De Angelis, Marco Mancini, MD, Roberto Latagliata, MD, Ida Carmosino, MD, Mauro Nanni, PhD, Bruno Rotoli, MD, Franco Mandelli, MD, Fabrizio Pane, MD
Journal: Blood
Blood (2006) 108 (11): 2158.
https://doi.org/10.1182/blood.V108.11.2158.2158
Published: 2006